EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

STING Protein‐Based In Situ Vaccine Synergizes CD4 + T, CD8 + T, and NK Cells for Tumor Eradication

Yanpu He, Celestine Hong, Shengnan Huang, Justin A Kaskow, Gil Covarrubias, Ivan S Pires, James C Sacane, Paula T Hammond, Angela M Belcher iD

Advanced Healthcare Materials · 2023-09 · 12 (24)

DOI: 10.1002/adhm.202300688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 21.04.2023. Verfasst von Yanpu He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. Hauptthemen laut MEDLINE: Neoplasms, Vaccines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stimulator of interferon genes (STING) signaling is a promising target in cancer immunotherapy, with many ongoing clinical studies in combination with immune checkpoint blockade (ICB). Existing STING‐based therapies largely focus on activating CD8 + T cell or NK cell‐mediated cytotoxicity, while the role of CD4 + T cells in STING signaling has yet to be extensively studied in vivo. Here, a distinct CD4‐mediated, protein‐based combination therapy of STING and ICB as an in situ vaccine, is reported. The treatment eliminates subcutaneous MC38 and YUMM1.7 tumors in 70–100% of mice and protected all cured mice against rechallenge. Mechanistic studies reveal a robust T H 1 polarization and suppression of T reg of CD4 + T cells, followed by an effective collaboration of CD4 + T, CD8 + T, and NK cells to eliminate tumors. Finally, the potential to overcome host STING deficiency by significantly decreasing MC38 tumor burden in STING KO mice is demonstrated, addressing the translational challenge for the 19% of human population with loss‐of‐function STING variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsVaccinesHumansCD8-Positive T-LymphocytesKiller Cells, NaturalCD4-Positive T-LymphocytesImmunotherapy

Stichwörter der Autor:innen

CD4+ T cellscancer immunotherapyimmune checkpoint blockadestimulator of interferon genes signaling

Substanzen

Vaccines

Autor:innen und Institutionen

  • Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Department of Material Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

ORCID-Profile: Angela M Belcher

Förderung

  • NCI NIH HHS

Zitieren

APA

He, Y., Hong, C., Huang, S., Kaskow, J. A., Covarrubias, G., Pires, I. S., Sacane, J. C., Hammond, P. T., & Belcher, A. M. (2023). STING Protein‐Based In Situ Vaccine Synergizes CD4 + T, CD8 + T, and NK Cells for Tumor Eradication. Advanced Healthcare Materials, 12(24). https://doi.org/10.1002/adhm.202300688

Vancouver

He Y, Hong C, Huang S, Kaskow JA, Covarrubias G, Pires IS, et al. STING Protein‐Based In Situ Vaccine Synergizes CD4 + T, CD8 + T, and NK Cells for Tumor Eradication. Advanced Healthcare Materials. 2023;12(24). doi:10.1002/adhm.202300688

BibTeX
@article{He2023,
  author = {He, Yanpu and Hong, Celestine and Huang, Shengnan and Kaskow, Justin A and Covarrubias, Gil and Pires, Ivan S and Sacane, James C and Hammond, Paula T and Belcher, Angela M},
  title = {STING Protein‐Based In Situ Vaccine Synergizes CD4 + T, CD8 + T, and NK Cells for Tumor Eradication},
  journal = {Advanced Healthcare Materials},
  year = {2023},
  volume = {12},
  number = {24},
  doi = {10.1002/adhm.202300688}
}
Kostenlos starten →